Ainos (AIMD) Risk Assessment

View and export this data going back to 1996. Start your Free Trial

What is Ainos Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Ainos is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Ainos's Risk Assessment

For the Medical Devices subindustry, Ainos's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ainos's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ainos's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Ainos's Risk Assessment falls into.

Ainos (NAS:AIMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Ainos Risk Assessment Related Terms

Thank you for viewing the detailed overview of Ainos's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Ainos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108

Website

https://www.ainos.com

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Executives

Meng Lin Sung	officer: Chief Financial Officer	8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee	director	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc	10 percent owner	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei	director	10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai	director, officer: Chairman, CEO, CFO	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai	director	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang	director	5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang	director	NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin	other: EVP - OPERATIONS	2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu	officer: Chief Financial Officer	8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu	director	9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai	director	105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen	director	1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen	officer: VP, CFO	4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore	director	402 FISH HATCHERY ROAD, HAMILTON MT 59840